{"product_id":"bio-techne-swot-analysis","title":"Bio-Techne SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBio-Techne’s resilient product portfolio and strong R\u0026amp;D pipeline position it well in life-science tools, but regulatory shifts and market competition warrant caution; uncover precise risks, financial context, and strategic levers in our full SWOT analysis. Purchase the complete, editable report to access investor-ready insights, an Excel matrix, and actionable recommendations for planning, pitching, or investing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leadership in High-Quality Reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBio-Techne, via its R\u0026amp;D Systems brand, holds a leading share in protein sciences—R\u0026amp;D Systems accounted for roughly 30% of Bio-Techne’s 2024 product revenue of $1.15B—driving repeat purchase from academic labs and Pharma for validated antibodies and proteins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Proportion of Recurring Consumable Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBio-Techne earns roughly 70% of revenue from consumables—reagents, assays, and proteins—creating predictable, subscription-like cash flow as labs replenish supplies; in FY2024 consumables drove ~68% of $1.17B revenue, supporting 10–12% adjusted EBITDA margins.\u003c\/p\u003e\n\u003cp\u003eThis recurring consumable mix cushions the company when capital-equipment spend drops: during 2020–2021 downturns consumable sales fell far less than instruments, keeping cash conversion positive.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Portfolio Across Life Sciences\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBio-Techne has diversified into protein analysis, diagnostics, and spatial biology, cutting reliance on any single product line; in 2025 these segments accounted for roughly 35%, 30%, and 15% of revenue respectively, reducing concentration risk.\u003c\/p\u003e\n\u003cp\u003eOperating across discovery and diagnostic stages lets Bio-Techne capture value at multiple pipeline points; its reagent and instrument sales feed both early-stage research and clinical labs, supporting 10%+ organic growth in 2024.\u003c\/p\u003e\n\u003cp\u003eThis broad exposure enables quick pivots into high-growth areas like spatial biology—projected CAGR ~18% through 2028—while core products (antibodies, assays) delivered stable gross margins near 65% in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Brand Equity and Academic Influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBio-Techne reagents appear in over 40,000 peer-reviewed papers, cementing the firm as a trusted lab standard and driving repeat purchases across academia and industry.\u003c\/p\u003e\n\u003cp\u003eThat academic entrenchment funnels customers into biopharma roles, supporting sustained demand and allowing price premiums; Bio-Techne reported 2024 product gross margins near 68%, reflecting pricing power.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e40,000+ citations in literature\u003c\/li\u003e\n\u003cli\u003e2024 product gross margin ~68%\u003c\/li\u003e\n\u003cli\u003eLoyal academic-to-industry customer flow\u003c\/li\u003e\n\u003cli\u003eHigh barrier for new entrants\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Profitability and Financial Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBio-Techne reported 2024 adjusted operating margin of about 26% and ended FY2024 with net cash of $850M, supporting R\u0026amp;D reinvestment and M\u0026amp;A without stressing the balance sheet.\u003c\/p\u003e\n\u003cp\u003eFree cash flow was $260M in FY2024, allowing share repurchases and dividend-like returns while funding product development and bolt-on acquisitions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 adj. operating margin ~26%\u003c\/li\u003e\n\u003cli\u003eNet cash ~$850M (FY2024)\u003c\/li\u003e\n\u003cli\u003eFree cash flow $260M (FY2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-Techne: Cash-rich protein sciences leader—68% consumables, 26% op margin, $1.15B product rev\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBio-Techne leads protein sciences (R\u0026amp;D Systems ≈30% of 2024 product revenue of $1.15B), with consumables driving ~68% of FY2024 $1.17B revenue and 10–12% adj. EBITDA margins; 2024 adj. operating margin ≈26%, net cash ≈$850M, FCF $260M. Spatial biology CAGR ~18% (to 2028); product gross margin ~68%; 40,000+ literature citations.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (product)\u003c\/td\u003e\n\u003ctd\u003e$1.15B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables %\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. Op Margin\u003c\/td\u003e\n\u003ctd\u003e26%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash\u003c\/td\u003e\n\u003ctd\u003e$850M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFCF\u003c\/td\u003e\n\u003ctd\u003e$260M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLit. citations\u003c\/td\u003e\n\u003ctd\u003e40,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear SWOT framework analyzing Bio-Techne’s strengths, weaknesses, opportunities, and threats to map its competitive position, growth drivers, and market risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT matrix tailored to Bio-Techne for fast, visual strategy alignment and prioritization of R\u0026amp;D and market expansion initiatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSensitivity to Biopharma R\u0026amp;D Spending Cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbout 55% of Bio-Techne’s 2024 revenue came from research reagents and instruments, tying sales closely to biotech\/pharma R\u0026amp;D budgets; when venture funding fell 28% in 2023 and global biopharma R\u0026amp;D growth slowed to 3% in 2024, Bio-Techne reported a mid-single-digit order decline in parts of its research tools business. This makes the company vulnerable to funding cycles, tighter capital markets, and high-rate led slowdowns that compress growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration Risks from Frequent Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBio-Techne’s growth via acquisitions (22 deals since 2015, ~USD 1.8bn capex 2018–2024) raises integration risk as merging cultures and product lines creates complexity and short-term inefficiencies.\u003c\/p\u003e\n\u003cp\u003eOverlapping portfolios and disparate IT systems have previously pushed SG\u0026amp;A higher; a missed-synergy deal could cut EPS growth—management warned 2024 guidance may fall 3–5% if integrations lag.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Volatile International Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBio-Techne earned about 42% of 2024 revenue from international markets, with China accounting for roughly 12% of total sales, exposing results to sharp swings after Beijing cut some life-science research funding in 2023; quarterly revenue has swung ±5–8% year-over-year in affected segments. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmaller Scale Compared to Industry Giants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBio-Techne leads in reagents and instruments but is smaller than conglomerates like Thermo Fisher Scientific (2024 revenue $61.6B) and Danaher ($32.0B), limiting scale and capital for giant deals.\u003c\/p\u003e\n\u003cp\u003eThat size gap hinders winning large enterprise contracts and multi-year government tenders where bundled offerings and volume discounts matter; competitors can cross-subsidize pricing across $10B+ portfolios.\u003c\/p\u003e\n\u003cp\u003eIn 2024 Bio-Techne revenue was $1.1B, making it harder to match bundled pricing and global service reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: Bio-Techne $1.1B vs Thermo Fisher $61.6B, Danaher $32.0B\u003c\/li\u003e\n\u003cli\u003eSmaller product breadth: limits bundled bids\u003c\/li\u003e\n\u003cli\u003eLess capital for multi-year, high-discount tenders\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Key Manufacturing Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBio-Techne relies on a small number of specialized manufacturing sites for high-quality biological reagents; a single-site disruption could cut supply and revenue sharply, as these products drove ~54% of 2024 revenue ($1.02B of $1.89B) and have long lead times for scale-up.\u003c\/p\u003e\n\u003cp\u003eReplacing capacity is costly and slow—building GMP (good manufacturing practice) biologics lines can take 12–36 months and $20–100M, so temporary outages risk lost contracts and customer churn.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~54% of 2024 revenue tied to specialized reagents\u003c\/li\u003e\n\u003cli\u003eGMP line setup 12–36 months, $20–100M\u003c\/li\u003e\n\u003cli\u003eSingle-site outage → supply shortage, lost contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-Techne at Risk: R\u0026amp;D \u0026amp; China Exposure, Rapid M\u0026amp;A Strains Scale and Guidance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy exposure to R\u0026amp;D cycles (55% research revenue) and China (12% sales) makes Bio-Techne vulnerable to funding slowdowns; mid-single-digit order dips occurred in 2024 after venture funding fell 28% in 2023. Rapid M\u0026amp;A (22 deals since 2015, ~$1.8B capex 2018–2024) raises integration and SG\u0026amp;A risk—management warned 2024 guidance could fall 3–5% if synergies miss. Scale gap (2024 revenue $1.1B vs Thermo $61.6B) limits bidding on large tenders. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch revenue\u003c\/td\u003e\n\u003ctd\u003e55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eM\u0026amp;A since 2015\u003c\/td\u003e\n\u003ctd\u003e22 deals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex 2018–2024\u003c\/td\u003e\n\u003ctd\u003e~$1.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitor revenue (Thermo Fisher)\u003c\/td\u003e\n\u003ctd\u003e$61.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eBio-Techne SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content shown is pulled from the final, editable file. You’re viewing a live excerpt of the real analysis document; the complete, detailed version becomes available immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752407118201,"sku":"bio-techne-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/bio-techne-swot-analysis.png?v=1772240630","url":"https:\/\/growthsharematrix.com\/products\/bio-techne-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}